Natural Pharmaceuticals, Inc. (NPI) is a global source for high-purity semi-synthetic active pharmaceutical ingredient (API) paclitaxel and docetaxel.
Natural Pharmaceuticals, Inc. (NPI), founded in 1998, produces a sustainable supply of semi-synthetic paclitaxel API for clinical research and commercial sales at competitive prices for the gobal market. NPI additionally produces docetaxel.
Yew-tree Derived Product
The company has millions of mature yew trees in nurseries located in the United States and a very aggressive and sustainable replanting program underway to assure a steady supply in the future. NPI cultivates yew trees for its multi-national operations which ultimately produce and deliver API paclitaxel and docetaxel to the customer.
Award-winning Chemistry
NPI utilizes novel chemistry in the extraction of primary taxanes from ornamental yew trees and subsequent conversion into paclitaxel. NPI’s chemical production technology received the Creative Invention Award of the American Chemical Society.
Higher Purity and Yield
The semi-synthetic paclitaxel and docetaxel produced by NPI is extremely pure. Its patented semi-synthetic process does not involve any molecule’s chiral centers, assuring molecular integrity. Furthermore, NPI’s semi-synthesis uses more of the available primary taxanes in the yew tree to produce higher yields, which assures an adequate supply and competitive pricing.
NPI Customers and Partners
NPI has customers in North America, Latin America, Europe, and East Asia. Our customers include oncology and non-oncology pharmaceutical manufacturers, medical device companies, as well as scientific researchers and universities. Multiple R&D projects are underway with corporate partners in innovative taxane programs.